- Associated Press - Monday, January 22, 2018

PARIS (AP) - France-based drugmaker Sanofi is buying U.S. hemophilia specialist Bioverativ for $11.6 billion in a deal that Sanofi says will boost its profile for fighting rare diseases.

The deal announced Monday is the latest such move in a pharmaceutical industry that’s seeing increasing interest in rare diseases.

Sanofi said in a statement that the boards of both companies approved the purchase, and that Sanofi will pay $105 per share in cash for all outstanding shares of Bioverativ. The Waltham, Massachusetts-based company focuses on blood disorders.

Bioverativ said it hopes its Eloctate and Alprolix hemophilia medications can reach a broader market thanks to Sanofi’s global infrastructure.

Sanofi’s strategy in the coming years includes expanding its rare disease portfolio, and hemophilia treatment is considered a growing market.

Copyright © 2018 The Washington Times, LLC.

The Washington Times Comment Policy

The Washington Times is switching its third-party commenting system from Disqus to Spot.IM. You will need to either create an account with Spot.im or if you wish to use your Disqus account look under the Conversation for the link "Have a Disqus Account?". Please read our Comment Policy before commenting.

 

Click to Read More

Click to Hide